Technology area: Computing & Software
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shandong Buchang Pharmaceuticals Co. Ltd. currently has 1 pending office action within the Computing & Software technology area. This action is being reviewed by 1 distinct examiner, which means the company's current interaction with the patent office is entirely centralized. Additionally, the portfolio's active prosecution is confined to 1 distinct art unit. This concentration suggests that the company is focusing its intellectual property efforts on a specific technological domain without the need to navigate multiple administrative groups.
The busiest examiner for this portfolio is STCLAIR, ANDREW D, who is assigned to 1 pending office action. Since the total count of pending actions for the company is 1, this examiner holds responsibility for all active matters. This arrangement provides a clear and direct line of communication between the applicant and the patent office. Practitioners can focus their strategy on the specific procedural requirements of STCLAIR, ANDREW D within the designated art unit. The lack of multiple examiners or art units simplifies the management of the company's current patent applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STCLAIR, ANDREW D | 1 | 60.1% | +25.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17914390 | Traditional Chinese medicine for dispersing lung qi and detoxicating | STCLAIR, ANDREW D | 356d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17914390 | Traditional Chinese medicine for dispersing lung qi and detoxicating | STCLAIR, ANDREW D | 356d overdue |
| Art Unit | Apps |
|---|---|
| 2178 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17914390 | Traditional Chinese medicine for dispersing lung qi and detoxicating | STCLAIR, ANDREW D | 2178 | §101 | Non-Final OA | 356d overdue | Pending | Sep 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShandong Buchang Pharmaceuticals Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrew D Stclair has the most, with 1 of Shandong Buchang Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Computing & Software (USPTO Tech Center 2100), based on where its pending office actions are examined.
